Agilon's Inflection: New CEO, Raised Guidance, and a 400% Stock Revival

A strong Q2 beat and full-year raise mark a turning point as clinical programs and data pipelines start paying off.

AGL · Earnings Call · 2026-08-05

A Quarter of Validation

When agilon health reported Q2 2026 results on August 5, the market responded with a ferocious rally—the stock is up over 400% in the last 90 days, a stunning reversal from a multi-year downtrend. The catalyst is not a single event but an accumulation of evidence that the company's transformation is finally showing up in the numbers. New CEO Tim O'Rourke, who joined in early May, framed it clearly: "We feel the results are evidence that our transformation efforts are gaining traction, our physician partnerships continue to strengthen, and our operating model is becoming increasingly resilient, scalable, and durable." The financial beat was decisive. Revenue came in at ~$1.5B, medical margin at $197M (vs. -$53M a year ago), and adjusted EBITDA at $70M (vs. -$83M). Critically, management raised full-year guidance for revenue, medical margin, and adjusted EBITDA (midpoint ~$5.8B, $485M, and $85M respectively). CFO Jeff Schwaneke explained the bridge: "Q2 performance compared to our previous midpoint was roughly $50 million ahead... the risk adjustment, there is a second half impact... I would call that roughly $19 million at the EBITDA line for an impact on the rest of the year." Revenue associated with improved diagnosis—driven by better risk adjustment—was a primary driver.

Clinical Programs and Data: The Silent Engine

The turnaround is not just a cyclical recovery; it reflects structural investments in clinical pathways and data infrastructure. Enhanced data pipelines now cover over 80% of payers, enabling member-level risk score calculation and earlier intervention. The CHF program, deployed across 90% of markets, has already cut inpatient first-diagnosis rates from ~25% to under 5%. Tim emphasized the broader ambition: "We are also expanding our pharmacy-integrated approach for heart failure patients as fewer than 10% of heart failure patients nationally are on the appropriate medications." This clinical focus is echoed in the company's top keywords, with PCP partner and patient outcomes dominating the latest quarter.

We believe Agilon sits at the center of where value-based care is going. By partnering with community-based primary care physicians and providing them with enhanced economics, technology, and clinical tools, we enable PCPs to focus on what they are trained to do—keeping patients healthy.
Timothy O’Rourke · 2026-08-05

Risk Adjustment and ACO: The Forward Levers

A significant portion of the beat came from improved risk adjustment, now estimated at ~3% year-over-year net of V28—double the prior estimate. Jeff noted, "The positive results and increase to our full year guidance were driven by better-than-expected performance in the diagnosis, assessment, and treatment of our members in 2025, and favorable medical expense development." This is not a one-off; the enhanced data pipeline provides ongoing visibility. Dates of service now develop more favorably, and the care coordination fee model offers upside as more contracts convert to full risk. On the ACO front, the recently announced ACO REACH results for 2024 showed $229M in gross savings and a 96% average quality score. Looking to 2027, the LEAD model and MSSP represent significant opportunities. Tim commented, "We are evaluating the best path forward for both existing and new ACO partners as we enter 2027, with the expectation for both to be positive contributors to our performance in the coming years."

What Changed and Why It Matters

The fundamental shift is in execution and confidence. The company has moved from defensive mode—exiting contracts, cutting costs, and shrinking membership—to a position where it can raise guidance and talk about re-engaging with partners. The operating income of $30M in Q2 2026 vs. a loss a year earlier confirms the turnaround. Membership declined year-over-year (437k vs. 498k MA members) but that was deliberate, and management now sees growth opportunities in existing markets, care coordination conversions, and ACO expansion. Cost trends are also moderating. Jeff stated, "We recorded a second quarter cost trend in the low 7% range, which reflects our prudent reserving approach given the limited paid claims data we have at the end of any given quarter." But the early signs of moderation—particularly in inpatient and ER—align with broader industry commentary. For investors, the story is no longer about survival but about scaling a proven model. The stock's 400% rally reflects the market's repricing of agilon as a growth vehicle again. The key risks remain contracting for 2027 and execution on clinical pathways, but the evidence this quarter suggests the foundation is real. As Tim concluded: "I am confident Agilon is on the right path. And that path leads to a genuinely better health care system for the communities and patients we serve." Prior calls had hinted at this inflection. In May, Jeff remarked, "The main change is our performance this quarter on risk adjustment. We now have more confidence going forward... that gives us more confidence in 2027 and beyond." (component 1656250514724544675) And in February, he said, "We feel pretty good that we have a solid foundation in order to... project forward as we think about a 2026 guide." (component 5525738637540256600) That foundation is now paying off.